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established based on the British Clinical guidelines for Immuno-
globulin Use, 2nd edition, July 2011 update.
Results 138 patients (average age 59.1, 58.7% female) received
IVIg. 44.1% of treatments were administered to hospitalised
patients.
Label indications were 67.4%: common variable immunodefi-
ciency (55/93), IgG immunodeficiency (13/93), idiopathic throm-
bocytopenic purpura (12/93), Guillain-Barré syndrome (6/93),
Kawasaki disease (3/93), secondary immunodeficiency (2/93),
hyperIgM immunodeficiency (1/93) and unspecified hypogam-
maglobulinaemia (1/93).
Off-label indications supported by clinical evidence were
21.0%: myasthenia gravis (7/29), multifocal motor neuropathy
(6/29), non-specific demyelinating neuropathy (4/29), chronic
inflammatory demyelinating polyradiculoneuropathy (3/29),
inclusion body myositis (3/29), autoimmune haemolytic anaemia
(2/29), polymyositis (1/29), dermatomyositis (1/29), Rassmusen
syndrome (1/29) and alloimmune thrombocytopenia (1/29).
Off-label indications not sufficiently supported by clinical evi-
dence were 5.8%: systemic vasculitits (2/8), scleroderma (2/8),
polyarteritis nodosa (2/8), microscopic polyarteritis (1/8), acute
disseminated encephalomyelitis (1/8).
Non-recommended indications were 5.8%: systemic lupus
erythematosus (3/8), epilepsy (2/8), proximal diabetic neuropathy
(1/8), aplastic anaemia (1/8) and paraneoplastic syndrome (1/8).
For each category, IVIg dispensed were 22 252.5 g, 16 632.5
g, 7287.5 g and 5247.5 g, respectively. Percentage expenditure
for each one was 41.4%, 34.2%, 13.9% and 10.5%, respectively
(of a total amount of 1 730 002C¼ ).
Conclusion Despite the fact that most of the dispensed IVIg
were used for label or for off-label supported by clinical evi-
dence indications, uses with unproven clinical benefit, even those
recommended, implies an important expense in our hospital.
Due to the frequent off-label use of IVIg, implementing a proto-
col would be useful to adjust IVIg treatments to the guideline
recommendations and to optimise its use.
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Background Over the counter medicines (OTCms) are widely
used in paediatrics but their conditions of use are difficult to
monitor as they do not need a prescription for purchasing. Even
though several studies have been conducted in the USA and Aus-
tralia, data are lacking in our country.
Purpose Our multidisciplinary team (1 clinical pharmacist, 2 pae-
diatricians, 1 researcher) analysed the use of OTCms in the
paediatric population. We focused on self-medication habits,
typology of medications and parents’ awareness about the poten-
tial drug interactions (DI) and adverse drug reactions (ADRs).
Material and methods We conducted a 4 week prospective study
by survey through a questionnaire delivered to parents waiting
for a paediatric visit in a medical practice office. Questions (n =
18) concerned: social and cultural overview, type of OTCms
utilised, self-medication use behaviour, drug characteristics,
impact of advertisements, knowledge and awareness of the possi-
bility of DI, inefficacy or ADRs.
Results 50 questionnaires were collected. 96% of those inter-
viewed were mothers. Mean age of parents was 41 years for
fathers (range 30–55) and 38 for mothers (range 20–51). Mean
number of sons was 1.66 (range 1–5) and their mean age was
6.21 years (range 17 days-16 years). Results showed a wide-
spread use of OTCms in the paediatric population (78%). Most
frequently they were administered after a doctor’s (59%) or
pharmacist’s (24%) advice. Most used OTCms classes were:
drugs for upper respiratory tract (58%) or gastrointestinal prob-
lems (9%), supplements/vitamins (18%) and analgesics (15%).
ADRs eventually detected by parents were reported to the pae-
diatrician/pharmacist by 76%. 72% of parents acquainted them-
selves with ADRs and potential DI. Parents reported the
medicine’s inefficacy to the paediatrician after 2–3 days (65%)
or different periods (35%), depending on disease severity. 31%
of parents declared to be influenced by advertisements.
Conclusion Parents were aware about the possibility of ADRs,
DI and inefficacy of OTCms. Although the data showed that the
parent-paediatrician relationship was important to address the
use of OTCms for the children, some parents were influenced
by advertisements. An improvement in the study is planned by
increasing the number of interviewed parents and the level of
detail.
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Background Cytomegalovirus (CMV) infection is the most com-
mon viral infection after solid organ transplantation, and is an
important cause of mortality and morbidity in this group of
patients. Valganciclovir is used to treat and prevent this
condition.
Purpose The aim of our study was to analyse the use of valganci-
clovir (indication of treatment, dosage and safety) in liver trans-
planted patients.
Material and methods Retrospective observational study that
included all patients that underwent liver transplantation in
2014 in our hospital. Electronic clinical history (SELENE), the
pharmacy service managing software (Farmatools) and an Excel
database of transplanted patients were used to collect the
information.
Results 38 patients underwent liver transplantation in our hospi-
tal in 2014. 34 patients were finally included (mean age 55
years) after surviving the postoperative period. Mean length of
stay in hospital was 26 days and mean discharge creatinine was
0.93 mg/dL. 11 patients (32.3%) were treated with valganciclo-
vir, 6 (55%) as treatment against CMV and the rest as prophy-
laxis (CMV seropositive donor and CMV seronegative receiver).
The dose used in prophylaxis was 900 mg/24 h for all patients
except one who received 450 mg/24 h because of reduced kid-
ney function; the dose used for treatment was 900 mg/12 h in
all patients as none presented with kidney malfunction. 8
patients (24%) had valganciclovir included in their treatment
after discharge. Mean duration of treatment with valganciclovir
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